Skip to content

Establishment and Characterization of Meningioma Patient-derived Organoids

Establishment and Characterization of Meningioma Patient-derived Organoids

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04478877
Enrollment
20
Registered
2020-07-21
Start date
2020-05-23
Completion date
2023-08-31
Last updated
2023-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meningioma

Brief summary

In this study, meningioma organoids will be established from patients' tissues and the characterization of the organoid will be performed.

Detailed description

Aims and Hypothesis to be tested: The investigators hypothesized that the derived organoid should have a similar morphological and genetic mutation signatures to the patient primary tissue. Study period: 1 year for patient recruitment and organoid generation from patient tumor Study population: 30 Study samples: Patient's meningioma tumor sample are collected from patients with surgical needs. Sample collected are used for organoid culture. Morphological and genetic characteristics will be compared between the patient tumor sample and the corresponding derived organoids Primary outcome measures: Whole exome sequencing data of patient tumor tissue and patients-derived organoids

Interventions

None listed

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult patients (aged \>18 years) with meningioma 2. Admission into Prince Wales hospitals neurosurgical services 3. Patients with surgical needs of meningioma removal

Exclusion criteria

1\. Patients (or next-of-kin as appropriate) refuse to participate into the study

Design outcomes

Primary

MeasureTime frameDescription
Whole exome sequencing data7 daysDNA extracted from patient tumor tissue and patients-derived organoids will be perform whole exome sequencing for genetic characterization.

Secondary

MeasureTime frameDescription
Immunostaining7 daysH&E staining and meningioma markers immunostaining

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026